Tyson MD 2nd, Nam JK, Joshi SS, Uchio EM, et al. Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial. Lancet Oncol 2026;27:983-993.
PMID: 42508433